Here’s what you need to know:
1. The NUsurface Meniscus Implant was developed by the biotechnology company Active Implants. It has been used in Europe under CE Mark since 2008.
2. The device is meant for patients with persistent knee pain caused by injured or deteriorated meniscus cartilage
3. Capital Regional Orthopaedic Associates is one of 10 sites throughout the United States participating in the “Verification of the Effectiveness of the NUsurface System,” or VENUS, clinical trial.
4. The meniscus replacement procedure at Capital Regional Orthopaedic Associates was performed by Richard Alfred, MD, and Maxwell Alley, MD.
More articles on devices and implants:
Fortimedix Surgical receives CE Mark approval for FMX314: 3 notes
Nasseo awarded NSF grant for spinal implant research: 4 notes
Global market for cervical total disc replacement devices to reach $1.75B by 2021: 5 notes
